CN115368336A - 一种天然产物elegansin D的合成方法 - Google Patents
一种天然产物elegansin D的合成方法 Download PDFInfo
- Publication number
- CN115368336A CN115368336A CN202210972063.8A CN202210972063A CN115368336A CN 115368336 A CN115368336 A CN 115368336A CN 202210972063 A CN202210972063 A CN 202210972063A CN 115368336 A CN115368336 A CN 115368336A
- Authority
- CN
- China
- Prior art keywords
- reaction
- compound
- elegansin
- natural product
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930014626 natural product Natural products 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 34
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 7
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 claims abstract description 6
- 229940125904 compound 1 Drugs 0.000 claims abstract description 6
- 238000005886 esterification reaction Methods 0.000 claims abstract description 5
- 238000006385 ozonation reaction Methods 0.000 claims abstract description 5
- 238000007259 addition reaction Methods 0.000 claims abstract description 4
- 238000005805 hydroxylation reaction Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 230000035484 reaction time Effects 0.000 claims description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 14
- 229940125898 compound 5 Drugs 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 229940126214 compound 3 Drugs 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- 229930004725 sesquiterpene Natural products 0.000 abstract description 8
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 abstract description 6
- 150000004354 sesquiterpene derivatives Chemical class 0.000 abstract description 5
- 150000001336 alkenes Chemical class 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- -1 sesquiterpene olefin Compound Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000006130 Horner-Wadsworth-Emmons olefination reaction Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种天然产物elegansin D合成方法,属于化学合成领域。本方法以倍半萜化合物1为原料,依次通过区域选择性脱水反应、加成反应、酯化反应、臭氧化反应、Horner‑Wadsworth‑Emmons反应和烯烃邻位羟基化反应,实现了天然产物elegansin D的合成。本发明具有反应步骤少、操作简便、产物选择性好、适合工业化生产等特点。
Description
技术领域
本发明涉及一种天然产物elegansin D的合成方法。
背景技术
众所周知,Elegansin D是一种从紫花山柰根茎中提取出来的二萜天然产物。由于其潜在芳香酶活性抑制剂作用,对预防和治疗乳腺癌具有一定的药用价值(J. Nat. Prod.2021, 84, 1738-1747),目前关于该天然产物的合成尚未报道。鉴于以上背景,开发一种简洁,成本低廉,适合工业化生成的天然产物elegansin D的化学合成方法十分重要。
发明内容
本发明的目的是解决上述现有技术的不足,提供一种反应步骤少、操作简便、产物选择性好、适合工业化生产的天然产物elegansin D的合成方法。
本发明解决其技术问题所采用的技术方案是:
一种天然产物elegansin D的合成方法,其特征在于,包括以下合成步骤:
上述的化合物1在二氯亚砜和三乙胺条件下,通过区域选择性脱水反应得到化合物2,与二氯亚砜和三乙胺的反应优先选择甲苯、二甲苯、二氯甲烷、氯仿为溶剂,反应温度为-78 °C,反应时间为1~3 h。
上述的化合物5分子内Horner-Wadsworth-Emmons反应优先选择的碱是NaH、tBuOK、LiHMDS。
本发明具有以下特点:
1. 以已知的倍半萜醇化合物1为起始原料,步骤少,产率相对比较理想,成本低,适合大批量生产。
2. 本发明合成路线反应条件比较容易控制, 容易实施。
附图说明
图1是本发明具体合成路线图。
具体实施方式
下面结合附图对本发明进一步说明:
如附图所示,一种天然产物elegansin D的合成方法,其特征在于,包括以下合成步骤:
进一步,上述的化合物1在二氯亚砜和三乙胺条件下,通过区域选择性脱水反应得到化合物2,与二氯亚砜和三乙胺的反应优先选择甲苯、二甲苯、二氯甲烷、氯仿为溶剂,反应温度为-78 °C,反应时间为1~3 h。
进一步,上述的化合物5分子内Horner-Wadsworth-Emmons反应优先选择的碱是NaH、tBuOK、LiHMDS。
实施例1:倍半萜烯烃化合物2(见附图)的合成。
将2.21 g化合物1(见附图)溶于50 mL二氯甲烷中,在氮气保护下于-78 °C依次加入5.1 mL三乙胺和1.4 mL二氯亚砜,并搅拌1~3 h反应结束后用饱和碳酸氢钠水溶液淬灭,并用二氯甲烷萃取三次,合并有机相,无水硫酸钠干燥。过滤浓缩柱层析提纯,得油状液体化合物1.71 g,收率为84%。1H NMR (400 MHz, CDCl3) δ (ppm): 9.87 (d, J = 4.9 Hz,1H), 4.92 (s, 1H), 4.50 (s, 1H), 2.42 (ddd, J = 13.7, 4.5, 2.2 Hz, 2H), 2.12– 1.99 (m, 1H), 1.77 – 1.67 (m, 1H), 1.66 – 1.51 (m, 4H), 1.50 – 1.37 (m,4H), 1.26 – 1.19 (m, 3H), 1.15 (s, 3H), 1.07 – 0.99 (m, 2H), 0.88 (s, 3H),0.86 (s, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm): 205.77, 145.03, 109.25, 67.86,53.95, 41.89, 39.89, 39.00, 36.71, 33.49, 33.42, 23.05, 21.90, 18.72, 16.02.
实施例2:倍半萜烯烃化合物3(见附图)的合成。
将2.14 g化合物2溶于20 mL四氢呋喃中,在0 °C下加入甲基溴化镁3.9 mL,并搅拌0.5~1 h,反应完全后用饱和氯化钠溶液淬灭,用乙酸乙酯萃取3次,无水硫酸钠干燥,过滤浓缩柱层析提纯,得到又装液体2.18 g,收率为95%。1H NMR (400 MHz, CDCl3) δ(ppm):5.04 (d, J = 1.7 Hz, 1H), 4.95 (s, 1H), 4.34 (dt, J = 6.6, 3.3 Hz, 1H), 2.33(ddd, J = 12.8, 5.0, 2.8 Hz, 1H), 2.11 – 1.95 (m, 1H), 1.93 – 1.80 (m, 2H),1.75 – 1.57 (m, 4H), 1.54 – 1.34 (m, 6H), 1.32 (s, 3H), 1.16 (dddd, J = 16.7,12.8, 7.3, 4.1 Hz, 3H), 1.02 (s, 3H), 0.85 (s, 3H), 0.84 (s, 3H). 13C NMR (101MHz, CDCl3) δ (ppm): 146.32, 109.46, 66.45, 62.05, 55.40, 42.07, 40.06,39.84, 38.75, 33.77, 33.51, 24.35, 23.44, 21.80, 19.22, 16.47.
实施例3:倍半萜烯烃化合物4(见附图)的合成。
将1.32 g化合物3和1.72 g 化合物7溶于10 mL二氯甲烷中,室温下加入1.73 gDCC,并在室温下搅拌2~3 h,过滤白色固体后浓缩柱层析提纯,得到又装液体1.99 g,收率为86%。1H NMR (400 MHz, CDCl3) δ (ppm): 5.46 (dd, J = 6.6, 1.9 Hz, 1H), 5.05(s, 1H), 4.96 (s, 1H), 4.32 – 3.92 (m, 4H), 3.09 – 2.74 (m, 2H), 2.34 (ddd, J= 12.7, 4.7, 2.4 Hz, 1H), 1.99 (td, J = 12.9, 5.4 Hz, 1H), 1.80 – 1.63 (m,3H), 1.50 (dtt, J = 17.8, 10.2, 3.6 Hz, 2H), 1.32 (td, J = 6.2, 5.3, 3.6 Hz,9H), 1.11 (qd, J = 13.2, 4.2 Hz, 2H), 1.00 (dd, J = 12.6, 2.9 Hz, 1H), 0.84(s, 3H), 0.83 (s, 3H), 0.79 (s, 3H). 13C NMR (101 MHz, CDCl3) δ(ppm):165.14,165.08, 144.54, 110.05, 69.97, 62.49, 62.43, 60.66, 56.06, 41.95, 39.92,39.10, 35.49, 34.15, 33.71, 33.46, 24.36, 21.66, 19.41, 19.10, 16.28, 16.22,15.93.
实施例4:倍半萜烯烃化合物5(见附图)的合成。
将977 mg化合物4溶于10 mL二氯甲烷中,在-78 °C下通入臭氧,溶液变成蓝色后,加入2 mL三乙胺,并在室温搅拌2 h,凝缩后得到产物5,无需进一步纯化。
实施例5:倍半萜烯烃化合物6(见附图)的合成。
将得到的产物5溶于四氢呋喃10 mL,加入113 mg NaH室温搅拌0.5~1 h。反应完全后加入饱和氯化铵溶液并淬灭,乙酸乙酯萃取3次,无水硫酸钠干燥,浓缩柱层析提纯,得到白色固体501 mg,收率为81%。1H NMR (400 MHz, CDCl3) δ (ppm) 5.78 (s, 1H), 4.76(t, J = 6.7 Hz, 1H), 2.48 (ddd, J = 12.6, 4.4, 2.3 Hz, 1H), 2.24 – 2.10 (m,1H), 1.97 – 1.89 (m, 1H), 1.88 – 1.80 (m, 1H), 1.79 (s, 1H), 1.61 (dt, J =13.6, 3.4 Hz, 1H), 1.57 – 1.47 (m, 2H), 1.46 – 1.40 (m, 1H), 1.35 (d, J = 6.7Hz, 3H), 1.24 – 1.11 (m, 2H), 1.08 – 0.97 (m, 1H), 0.90 (s, 3H), 0.88 (s,3H), 0.80 (s, 3H). 13C NMR (101 MHz, CDCl3) δ(ppm): 163.43, 159.65, 113.02,72.22, 56.07, 54.73, 41.84, 38.25, 36.07, 33.48, 33.37, 24.53, 23.69, 21.34,18.81, 14.11.
实施例6:天然产物 elegansin D(见附图)的合成。
将366 mg化合物5溶于2 mL二氧六环中,加入二氧化硒185 mg,在封管里加热至120 °C,搅拌4~6 h。待反应冷却至室温后,用硅藻土过滤,浓缩柱层析提纯,得到白色固体266 mg,收率为69%。1H NMR (400 MHz, CDCl3) δ (ppm): 5.88 (d, J = 1.5 Hz, 1H),4.81 (d, J = 6.8 Hz, 1H), 4.47 (t, J = 2.4 Hz, 1H), 2.37 (s, 1H), 2.06 – 1.94(m, 1H), 1.85 (dd, J = 12.5, 1.6 Hz, 1H), 1.75 – 1.42 (m, 7H), 1.38 (d, J =6.8 Hz, 3H), 1.30 – 1.06 (m, 3H), 0.89 (d, J = 2.9 Hz, 6H), 0.81 (s, 3H). 13CNMR (101 MHz, CDCl3) δ (ppm): 163.42, 158.90, 113.60, 72.82, 70.60, 50.66,47.12, 42.18, 41.84, 38.13, 33.14, 33.01, 31.92, 23.24, 21.31, 18.89, 13.39.
本发明涉及倍半萜烯醇的选择性消除反应、酯化反应、臭氧化反应、Horner-Wadsworth-Emmons反应等,合成一种天然产物elegansin D。上述具体实施举例仅是本发明的较佳实例而已,并非是对本发明作其它形式的限制。
Claims (3)
1.一种天然产物elegansin D的合成方法,其特征在于,包括以下合成步骤:
2.根据权利要求1所述的一种天然产物elegansin D的合成方法,其特征在于化合物1在二氯亚砜和三乙胺条件下,通过区域选择性脱水反应得到化合物2,与二氯亚砜和三乙胺的反应优先选择甲苯、二甲苯、二氯甲烷、氯仿为溶剂,反应温度为-78 °C,反应时间为1~3h。
3.根据权利要求1所述的一种天然产物elegansin D的合成方法,其特征在于化合物5分子内Horner-Wadsworth-Emmons反应优先选择的碱是NaH、tBuOK、LiHMDS。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210972063.8A CN115368336B (zh) | 2022-08-15 | 2022-08-15 | 一种天然产物elegansin D的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210972063.8A CN115368336B (zh) | 2022-08-15 | 2022-08-15 | 一种天然产物elegansin D的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115368336A true CN115368336A (zh) | 2022-11-22 |
CN115368336B CN115368336B (zh) | 2023-11-14 |
Family
ID=84066179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210972063.8A Active CN115368336B (zh) | 2022-08-15 | 2022-08-15 | 一种天然产物elegansin D的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115368336B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105837549A (zh) * | 2016-04-18 | 2016-08-10 | 哈尔滨工业大学(威海) | 一种海洋萜类天然产物ent-chromazonarol的合成方法 |
-
2022
- 2022-08-15 CN CN202210972063.8A patent/CN115368336B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105837549A (zh) * | 2016-04-18 | 2016-08-10 | 哈尔滨工业大学(威海) | 一种海洋萜类天然产物ent-chromazonarol的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115368336B (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guindon et al. | Regiocontrolled opening of cyclic ethers using dimethylboron bromide | |
JP6980648B2 (ja) | 3−ヒドロキシ−3,6−ジメチルヘキサヒドロベンゾフラン−2−オンおよびその誘導体の製造 | |
JP2009531446A (ja) | タキサン誘導体の合成のためのコンバージェントプロセス | |
CA2634746A1 (en) | Processes for taxane derivatives and intermediates useful therein | |
HU207288B (en) | Process for enenthioselective producing phenyl-isoserine derivatives | |
AU706406B2 (en) | Paclitaxel synthesis from precursor compounds and methods of producing the same | |
CA2583366C (en) | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin iii | |
JP4144919B2 (ja) | バッカチンiiiおよびその誘導体類の10−デアセチルバッカチンiiiからの製造方法 | |
CA2222421C (en) | C-2' hydroxyl-benzyl protected, n-carbamate protected (2r,3s)-3-phenylisoserine and production process therefor | |
CA2222919A1 (en) | Paclitaxel synthesis from precursor compounds and methods of producing the same | |
US5750736A (en) | Method for acylating 10-deacetylbaccatin III selectively at the c-10 position | |
Booker-Milburn et al. | A concise synthesis of 7-desmethylasteriscanolide and the discovery of an unusual fragmentation reaction to the related asteriscunolide skeleton | |
CN115368336B (zh) | 一种天然产物elegansin D的合成方法 | |
JP3445973B2 (ja) | パクリタクセルおよびその類似体の半合成に有用な中間体ならびに方法 | |
JP2010513267A (ja) | ドセタキセルの製造方法及びそれに用いられる中間体 | |
US6066749A (en) | Method for conversion of C-2'-O-protected-10-hydroxy taxol to c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis | |
US5914411A (en) | Alternate method for acylating 10-deacetylbaccatin III selectively at the C-10 position | |
RU2264394C2 (ru) | Способ получения производных баккатина iii | |
US6048990A (en) | Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position | |
Barrero et al. | Enantiospecific syntheses of the potent bioactives nagilactone F and the mould metabolite LL-Z1271α an evaluation of their allelopathic potential | |
AU745731B2 (en) | Methods and useful intermediates for paclitaxel synthesis from C-7, C-10 di-CBZ baccatin III | |
JP5154546B2 (ja) | タキサン誘導体の調製法 | |
Kanishi et al. | Synthesis of macrocyclic (nnn)(1, 3, 5) cyclophane polylactones. | |
ES2316555T3 (es) | Reacciones de adicion sin catalizar. | |
Braussaud et al. | Synthesis of cyclobutanetricarboxylic acid derivatives via intramolecular [2+ 2] photocycloaddition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |